vs
Side-by-side financial comparison of APPIAN CORP (APPN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
APPIAN CORP is the larger business by last-quarter revenue ($202.9M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -2.5%, a 4.2% gap on every dollar of revenue. On growth, APPIAN CORP posted the faster year-over-year revenue change (21.7% vs 5.0%). Over the past eight quarters, APPIAN CORP's revenue compounded faster (16.4% CAGR vs -0.2%).
Appian Corporation is an American cloud computing and enterprise software company headquartered in McLean, Virginia, part of the Dulles Technology Corridor. The company sells a platform as a service (PaaS) for building enterprise software applications. It is focused on low-code development, process mining, business process management, and case management markets in North America, Europe, the Middle East and Southeast Asia.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
APPN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $202.9M | $177.4M |
| Net Profit | $-5.1M | $2.9M |
| Gross Margin | 64.8% | — |
| Operating Margin | -0.3% | 3.9% |
| Net Margin | -2.5% | 1.6% |
| Revenue YoY | 21.7% | 5.0% |
| Net Profit YoY | 62.6% | — |
| EPS (diluted) | $-0.06 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $202.9M | $196.9M | ||
| Q3 25 | $187.0M | $179.5M | ||
| Q2 25 | $170.6M | $181.1M | ||
| Q1 25 | $166.4M | $168.9M | ||
| Q4 24 | $166.7M | $187.3M | ||
| Q3 24 | $154.1M | $168.6M | ||
| Q2 24 | $146.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-5.1M | — | ||
| Q3 25 | $7.8M | $5.4M | ||
| Q2 25 | $-312.0K | $-4.8M | ||
| Q1 25 | $-1.2M | $4.8M | ||
| Q4 24 | $-13.6M | — | ||
| Q3 24 | $-2.1M | $-143.5M | ||
| Q2 24 | $-43.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 64.8% | 79.5% | ||
| Q3 25 | 75.8% | 80.9% | ||
| Q2 25 | 74.3% | 77.4% | ||
| Q1 25 | 76.6% | 79.7% | ||
| Q4 24 | 67.8% | 78.7% | ||
| Q3 24 | 75.9% | 76.9% | ||
| Q2 24 | 73.1% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -0.3% | 1.2% | ||
| Q3 25 | 7.0% | 3.5% | ||
| Q2 25 | -6.4% | 4.7% | ||
| Q1 25 | -0.5% | 1.2% | ||
| Q4 24 | 3.0% | 13.2% | ||
| Q3 24 | -4.6% | -82.8% | ||
| Q2 24 | -26.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -2.5% | — | ||
| Q3 25 | 4.2% | 3.0% | ||
| Q2 25 | -0.2% | -2.7% | ||
| Q1 25 | -0.7% | 2.8% | ||
| Q4 24 | -8.2% | — | ||
| Q3 24 | -1.4% | -85.1% | ||
| Q2 24 | -29.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.06 | $0.05 | ||
| Q3 25 | $0.10 | $0.12 | ||
| Q2 25 | $0.00 | $-0.11 | ||
| Q1 25 | $-0.02 | $0.10 | ||
| Q4 24 | $-0.18 | $0.38 | ||
| Q3 24 | $-0.03 | $-3.11 | ||
| Q2 24 | $-0.60 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $187.2M | $144.3M |
| Total DebtLower is stronger | $240.8M | — |
| Stockholders' EquityBook value | $-47.0M | $653.9M |
| Total Assets | $691.4M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $187.2M | $238.4M | ||
| Q3 25 | $191.6M | $246.3M | ||
| Q2 25 | $184.8M | $445.9M | ||
| Q1 25 | $199.7M | $493.6M | ||
| Q4 24 | $159.9M | $484.6M | ||
| Q3 24 | $99.2M | $453.8M | ||
| Q2 24 | $120.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $240.8M | $372.2M | ||
| Q3 25 | $245.7M | $376.7M | ||
| Q2 25 | $245.6M | $580.5M | ||
| Q1 25 | $248.0M | $583.4M | ||
| Q4 24 | $250.4M | $585.3M | ||
| Q3 24 | $252.8M | — | ||
| Q2 24 | $254.0M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-47.0M | $693.1M | ||
| Q3 25 | $-48.5M | $727.2M | ||
| Q2 25 | $-53.7M | $757.8M | ||
| Q1 25 | $-31.7M | $798.5M | ||
| Q4 24 | $-32.6M | $778.3M | ||
| Q3 24 | $-49.8M | $749.6M | ||
| Q2 24 | $-45.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $691.4M | $1.3B | ||
| Q3 25 | $611.7M | $1.3B | ||
| Q2 25 | $590.7M | $1.5B | ||
| Q1 25 | $592.9M | $1.6B | ||
| Q4 24 | $621.0M | $1.6B | ||
| Q3 24 | $549.9M | $1.5B | ||
| Q2 24 | $554.6M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1M | — |
| Free Cash FlowOCF − Capex | $270.0K | — |
| FCF MarginFCF / Revenue | 0.1% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $59.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.1M | $43.7M | ||
| Q3 25 | $18.7M | $60.8M | ||
| Q2 25 | $-1.9M | $12.0M | ||
| Q1 25 | $45.0M | $35.5M | ||
| Q4 24 | $13.9M | $33.1M | ||
| Q3 24 | $-8.2M | $53.9M | ||
| Q2 24 | $-17.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $270.0K | $43.5M | ||
| Q3 25 | $18.1M | $57.0M | ||
| Q2 25 | $-3.1M | $9.3M | ||
| Q1 25 | $44.3M | $26.9M | ||
| Q4 24 | $13.4M | $31.0M | ||
| Q3 24 | $-8.6M | $49.8M | ||
| Q2 24 | $-18.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 22.1% | ||
| Q3 25 | 9.7% | 31.7% | ||
| Q2 25 | -1.8% | 5.1% | ||
| Q1 25 | 26.6% | 15.9% | ||
| Q4 24 | 8.0% | 16.6% | ||
| Q3 24 | -5.6% | 29.6% | ||
| Q2 24 | -12.5% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 0.1% | ||
| Q3 25 | 0.3% | 2.2% | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.4% | 5.1% | ||
| Q4 24 | 0.3% | 1.1% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 0.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.39× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APPN
| Subscriptions Software And Support | $162.3M | 80% |
| Professional Services | $40.6M | 20% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
